UNSPSC 51162729: Neltenexine

This classification denotes a mucolytic agent with the molecular formula C18H20Br2N2O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) U942DGM90X, chemically known as 4,6-dibromo-alpha-((trans-4-hydroxycyclohexyl)amino)-2-thiophene-carboxy-o-toluidide but more generally known as neltenexine, which bears US NIH Compound Identifier 3047787. European Medicines Agency schedules Neltenexine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09187MIG.

UNSPSC 51162729 Neltenexine (Commodity) describes pharmaceutical products and services for parenteral and emergency-response applications that state and local health and correctional agencies are actively procuring. The code encompasses parenteral nutrition solutions, intravenous products, naloxone, and drug deactivation systems delivered to correctional facilities, community health departments, and other public health entities. State correctional departments and county health departments dominate the issuing bodies, with procurement tied directly to medical necessity and public health mandates. Work scope includes preparation and delivery of customized parenteral nutrition bags meeting strict turnaround requirements (24 hours for TPN/PPN, 8 hours for other parenteral products), supply chain management, and compliance with controlled-substance handling and documentation protocols specific to correctional or emergency-response settings.

The Washington State Department of Corrections and Seminole County, Florida represent the most recent active buyers under this code. The Washington DOC issued RFQ RFQQK13020 on September 8, 2026 (due October 7, 2026) soliciting parenteral products, services, and equipment for eight correctional facilities across three regions, with multiple contractor awards anticipated and a contract term running November 26, 2026 through June 30, 2030; the solicitation emphasizes small-business, minority-owned, women-owned, and veteran-owned enterprise participation under Washington State set-aside targets. Seminole County, Florida issued an IFB (IFB60459723LAS) posted June 30, 2026 seeking 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly deliveries to the county community health building. Both opportunities reflect concentrated activity in Washington State and Florida, with scope and procurement urgency driven by correctional health compliance and community opioid-response mandates.